In many healthcare systems, particularly those operating under constrained resources, access to innovative therapies is not driven solely by list prices. It is often shaped by a less visible, yet highly impactful factor: dose strategy.
While dosing is traditionally viewed as a purely clinical choice, it directly affects market access fundamentals, including public budgets, the number of patients treated, treatment continuity, adherence, and long-term sustainability.
From dose to coverage
In settings with capped budgets, per-unit import duties, or complex logistics, well-documented dose optimization strategies can increase patient coverage within a fixed budget, without compromising clinical outcomes when evidence supports equivalence.
Weight-based dosing, induction-maintenance differentiation, or progressive titration can also help reduce:
- wastage linked to vial sizes,
- treatment discontinuations,
- dose-related adverse events that negatively impact adherence.
A lever for equity and sustainability
Beyond cost containment, dose optimization is a powerful health equity tool. Simpler, better-tolerated regimens improve persistence and translate into real, sustained access for patients.
For payers and policymakers, this enables more sophisticated reimbursement frameworks, including differentiated pricing for induction versus maintenance phases or persistence-based reimbursement conditions.
Governance matters
Dose optimization must always be underpinned by:
- solid clinical or real-world evidence,
- enhanced pharmacovigilance,
- clear governance separating medical, economic, and commercial considerations.
When properly framed, dose optimization moves beyond a technical adjustment and becomes a strategic pillar of pharmaceutical policy and public-private partnerships.
By Access Focus